Outlook: Emerging cancer immunotherapy player
Medigene’s purchase of Trianta Immunotherapies and subsequent €15.9m capital raise completes its transformation into an emerging cancer immunotherapy player. Medigene is now focused on developing Trianta’s three technology platforms for haematological malignancies. The fresh finance provides an opportunity to deliver first clinical proof-of-concept by 2016, initially for its dendritic cell (DC) based cancer vaccines, the most advanced technology in Phase I/II studies for AML and prostate cancer. We value Medigene at €99m, or €7.15 per share.Medigene is a biopharmaceutical company that focuses on the research and development of drugs to treat cancer and autoimmune diseases. Co.'s segments are: marketed products and drug candidates. Co.'s marketed products segment consists of the drug Veregen®, which is an ointment for the treatment of external genital warts. Co.'s drug candidates segment consists of: EndoTAG®-1, which is for the indication pancreatic cancer and triple-negative breast cancer; RhuDex®, which is a modifying agent for the oral treatment of autoimmune diseases; and adeno-associated virus-like particles, which provides potential as prophylactic and therapeutic vaccines, for example, against cancer and infections.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.